186 related articles for article (PubMed ID: 35220402)
1. Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
Komrokji RS; Platzbecker U; Fenaux P; Zeidan AM; Garcia-Manero G; Mufti GJ; Santini V; Díez-Campelo M; Finelli C; Jurcic JG; Greenberg PL; Sekeres MA; DeZern AE; Savona MR; Shetty JK; Ito R; Zhang G; Ha X; Backstrom JT; Verma A
Leukemia; 2022 May; 36(5):1432-1435. PubMed ID: 35220402
[No Abstract] [Full Text] [Related]
2. New drugs for myeloid neoplasms with ring sideroblasts: Luspatercept vs imetelstat.
Tefferi A
Am J Hematol; 2021 Jul; 96(7):761-763. PubMed ID: 33861878
[No Abstract] [Full Text] [Related]
3. Clinical characteristics of Japanese patients with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
Edahiro Y; Ochiai T; Hashimoto Y; Morishita S; Shirane S; Inano T; Furuya C; Koike M; Noguchi M; Usuki K; Shiratsuchi M; Nakajima K; Ohtsuka E; Tanaka H; Kawata E; Nakamae M; Ueda Y; Aota Y; Sugita Y; Ohara S; Yamasaki S; Asagoe K; Yoshida S; Yamanouchi J; Suzuki S; Kondo T; Kanisawa Y; Toyama K; Omura H; Mizuchi D; Sakamaki S; Ando M; Komatsu N
Int J Hematol; 2023 Jul; 118(1):47-53. PubMed ID: 37058247
[TBL] [Abstract][Full Text] [Related]
4. Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
Lanino L; Restuccia F; Perego A; Ubezio M; Fattizzo B; Riva M; Consagra A; Musto P; Cilloni D; Oliva EN; Palmieri R; Poloni A; Califano C; Capodanno I; Itri F; Elena C; Fozza C; Pane F; Pelizzari AM; Breccia M; Di Bassiano F; Crisà E; Ferrero D; Giai V; Barraco D; Vaccarino A; Griguolo D; Minetto P; Quintini M; Paolini S; Sanpaolo G; Sessa M; Bocchia M; Di Renzo N; Diral E; Leuzzi L; Genua A; Guarini A; Molteni A; Nicolino B; Occhini U; Rivoli G; Bono R; Calvisi A; Castelli A; Di Bona E; Di Veroli A; Ferrara F; Fianchi L; Galimberti S; Grimaldi D; Marchetti M; Norata M; Frigeni M; Sancetta R; Selleri C; Tanasi I; Tosi P; Turrini M; Giordano L; Finelli C; Pasini P; Naldi I; Santini V; Della Porta MG;
Am J Hematol; 2023 Aug; 98(8):E204-E208. PubMed ID: 37222267
[No Abstract] [Full Text] [Related]
5. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
Fenaux P; Platzbecker U; Mufti GJ; Garcia-Manero G; Buckstein R; Santini V; Díez-Campelo M; Finelli C; Cazzola M; Ilhan O; Sekeres MA; Falantes JF; Arrizabalaga B; Salvi F; Giai V; Vyas P; Bowen D; Selleslag D; DeZern AE; Jurcic JG; Germing U; Götze KS; Quesnel B; Beyne-Rauzy O; Cluzeau T; Voso MT; Mazure D; Vellenga E; Greenberg PL; Hellström-Lindberg E; Zeidan AM; Adès L; Verma A; Savona MR; Laadem A; Benzohra A; Zhang J; Rampersad A; Dunshee DR; Linde PG; Sherman ML; Komrokji RS; List AF
N Engl J Med; 2020 Jan; 382(2):140-151. PubMed ID: 31914241
[TBL] [Abstract][Full Text] [Related]
6. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS).
Montalban-Bravo G; Kanagal-Shamanna R; Darbaniyan F; Siddiqui MT; Sasaki K; Wei Y; Yang H; Chien KS; Naqvi K; Jabbour E; Kadia TM; Daver N; DiNardo C; Ravandi F; Pemmaraju N; Bose P; Verstovsek S; Pierce S; Bueso-Ramos C; Patel K; Do KA; Kantarjian H; Garcia-Manero G
Am J Hematol; 2021 Jul; 96(7):E246-E249. PubMed ID: 33811786
[No Abstract] [Full Text] [Related]
7. Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts.
Farrukh F; Chetram D; Al-Kali A; Foran J; Patnaik M; Badar T; Begna K; Hook C; Hogan W; McCullough KB; Mangaonkar A; He R; Gangat N; Tefferi A
Am J Hematol; 2022 Jun; 97(6):E210-E214. PubMed ID: 35293000
[No Abstract] [Full Text] [Related]
8. Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts.
Mies A; Hermine O; Platzbecker U
Curr Hematol Malig Rep; 2016 Dec; 11(6):416-424. PubMed ID: 27595736
[TBL] [Abstract][Full Text] [Related]
9. Clinical analysis and literature review of a case with the myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
Long B; Shi H; Zhu C
Hematology; 2020 Dec; 25(1):283-285. PubMed ID: 32657243
[No Abstract] [Full Text] [Related]
10. Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).
Nicolosi M; Mudireddy M; Vallapureddy R; Gangat N; Tefferi A; Patnaik MM
Am J Hematol; 2018 Jan; 93(1):E27-E30. PubMed ID: 29067707
[No Abstract] [Full Text] [Related]
11. JAK2 exon 12 mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Not an exclusive mutation to polycythaemia vera.
Inano T; Araki M; Morishita S; Imai M; Yasuda H; Nitta H; Ito M; Edahiro Y; Ochiai T; Misawa K; Fukuda Y; Ohsaka A; Komatsu N
Br J Haematol; 2019 Oct; 187(1):e27-e31. PubMed ID: 31418453
[No Abstract] [Full Text] [Related]
12. Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis with co-mutated JAK2 and SF3B1.
Reinig EF; He R
Blood; 2017 Feb; 129(5):656. PubMed ID: 28153838
[No Abstract] [Full Text] [Related]
13. Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts.
Zeidan AM; Platzbecker U; Garcia-Manero G; Sekeres MA; Fenaux P; DeZern AE; Greenberg PL; Savona MR; Jurcic JG; Verma AK; Mufti GJ; Buckstein R; Santini V; Shetty JK; Ito R; Zhang J; Zhang G; Ha X; Backstrom JT; Komrokji RS
Blood; 2022 Nov; 140(20):2170-2174. PubMed ID: 35797468
[TBL] [Abstract][Full Text] [Related]
14. Luspatercept in Myelodysplastic Syndromes: Who and When?
Komrokji RS
Hematol Oncol Clin North Am; 2020 Apr; 34(2):393-400. PubMed ID: 32089218
[TBL] [Abstract][Full Text] [Related]
15. Luspatercept for the treatment of congenital sideroblastic anemia: Two case reports.
Shao Y; He L; Ding S; Fu R
Curr Res Transl Med; 2024 Mar; 72(1):103438. PubMed ID: 38244303
[TBL] [Abstract][Full Text] [Related]
16. Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis.
Komrokji R; Melody M; Al Ali N; Chan O; Klimek V; Ball BJ; Sekeres MA; Lucas G; Maciejewski JP; Sallman DA; Padron E; Kuykendall A; Lasho T; Al-Kali A; Naqvi K; Steensma DP; Garcia-Manero G; Patnaik MM
Leuk Lymphoma; 2022 Jan; 63(1):199-204. PubMed ID: 34448437
[TBL] [Abstract][Full Text] [Related]
17. Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future.
Nathan DI; Feld J; El Jamal SM; Mascarenhas J; Tremblay D
Leuk Res; 2022 Apr; 115():106820. PubMed ID: 35279478
[TBL] [Abstract][Full Text] [Related]
18. Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough.
Patnaik MM; Tefferi A
Am J Hematol; 2023 Aug; 98(8):1171-1175. PubMed ID: 37345627
[No Abstract] [Full Text] [Related]
19. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management".
Patnaik MM; Tefferi A
Am J Hematol; 2021 Mar; 96(3):379-394. PubMed ID: 33428785
[TBL] [Abstract][Full Text] [Related]
20. Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts.
Schulz F; Nachtkamp K; Kasprzak A; Gattermann N; Haas R; Germing U
Expert Rev Hematol; 2021 Jun; 14(6):509-516. PubMed ID: 34161752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
